Review Article
The essence of real-world study in cancer research
Translational Breast Cancer Research
2020;
1:
17
(30 July 2020)
Original Article
Neoadjuvant chemotherapy versus surgery as the initial option for T3 breast cancer (>5 cm): real-world evidence from the Chinese Society of Clinical Oncology Breast Cancer database
Translational Breast Cancer Research
2020;
1:
16
(30 July 2020)
Original Article
Analysis of the treatment patterns and safety of early breast cancer patients during the COVID-19 pandemic
Translational Breast Cancer Research
2020;
1:
15
(30 July 2020)
Original Article
Breast cancer patients with low estrogen receptor expression gain no significant survival benefit from endocrine therapy: a real-world study from China
Translational Breast Cancer Research
2020;
1:
14
(30 July 2020)
Original Article
Pyrotinib plus capecitabine for human epidermal factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study
Translational Breast Cancer Research
2020;
1:
13
(30 July 2020)
Editorial
How to optimize real-world study: concept, opportunities, and evidence quality
Translational Breast Cancer Research
2020;
1:
12
(30 July 2020)
Editorial
Pyrotinib: a new promising targeted agent for human epidermal growth factor receptor 2-positive breast cancer
Translational Breast Cancer Research
2020;
1:
11
(30 July 2020)
Editorial
The counterattack of anti-HER2 small molecule compounds has started
Translational Breast Cancer Research
2020;
1:
10
(30 July 2020)
Meet the Professor
Dr. Zefei Jiang: our journey beyond the stars and seas
Translational Breast Cancer Research
2020;
1:
9
(10 April 2020)
Case Report
Pyrotinib for metastatic breast cancer after multi-anti-HER2 targeted therapy: a case report
Translational Breast Cancer Research
2020;
1:
8
(10 April 2020)
Case Report
Optimized first-line therapy for stage IV breast cancer brings long-term disease-free survival: a case report and biological analysis
Translational Breast Cancer Research
2020;
1:
7
(10 April 2020)
Review Article
Tumor microenvironment and future targets of immunotherapy in breast cancer
Translational Breast Cancer Research
2020;
1:
6
(10 April 2020)
Review Article
Why ACE—overview of the development of the subtype-selective histone deacetylase inhibitor chidamide in hormone receptor positive advanced breast cancer
Translational Breast Cancer Research
2020;
1:
5
(10 April 2020)
Guideline
CSCO BC guideline: updates for HER2 positive breast cancer in 2020
Translational Breast Cancer Research
2020;
1:
4
(10 April 2020)
Guideline
CSCO BC guideline: updates for hormone receptor-positive breast cancer in 2020
Translational Breast Cancer Research
2020;
1:
3
(10 April 2020)
Editorial
New therapeutic avenue of epigenetic modulations in cancer
Translational Breast Cancer Research
2020;
1:
2
(10 April 2020)
Foreword
Welcome to Translational Breast Cancer Research
Translational Breast Cancer Research
2020;
1:
1
(10 April 2020)